Last updated on March 2018

Human Epidermal Growth Factor Receptor 2 (HER2) Positive Unresectable Locally Advanced or Metastatic Breast Cancer Disease Registry Study

Brief description of study

This disease registry is a prospective, multicenter non-interventional study designed to observe the different anticancer treatment regimens and their sequencing throughout the course of the disease in participants with unresectable locally advanced breast cancer (LABC) or metastatic breast cancer (mBC) and to describe the clinical outcome for each treatment regimen measured as progression-free survival.

Clinical Study Identifier: NCT02393924

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: ML29659 ...

Forth Valley Royal Hospital ; Oncology Department
Larbert, United Kingdom
  Connect »